• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Lymphoma Myeloma Leuk . Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitini

tetano

Editor, Senior Moderator
Clin Lymphoma Myeloma Leuk


. 2020 Jun 25;S2152-2650(20)30312-8.
doi: 10.1016/j.clml.2020.06.014. Online ahead of print.
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib


Francine M Foss[SUP] 1 [/SUP], Ami Rubinowitz[SUP] 2 [/SUP], Marie L Landry[SUP] 3 [/SUP], Iris Isufi[SUP] 4 [/SUP], Lohith Gowda[SUP] 4 [/SUP], Stuart Seropian[SUP] 4 [/SUP], Sarah Perreault[SUP] 5 [/SUP], Sheela V Shenoi[SUP] 6 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.

Keywords: Allogeneic stem cell transplantation; COVID-19; Graft-versus-host disease; Immunocompromised; JAK inhibitor.
 
Back
Top Bottom